In addition to CCT-tubulin interactions being of interest for considering the development of new anti-cancer therapeutics, CCT also interacts with other drivers of cell cycle progression, leading to the potential to block various phases of the cell cycle via interrupting CCT activity. Here, FLVCR2 is linked to cancer.